Skip to main content

Table 4 Cyberknife treatment characteristics (by patients)

From: A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases

Patients Hepatic (n = 75) Lung (n = 15) All Patients (n = 90)
Dose per fractions, n (%)    
 6 0 1 1 (1,1%)
 9 2 0 2 (2,2%°
 10 31 (41%) 1 32 (35,6%)
 12 3 0 3 (3,3%)
 13 2 0 2 (2,2%)
 15 37 (49%) 11 (73%) 48 (53,3%)
 20 0 2 2 (2,2%)
Total dose, n (%)    
 27 1 0 1,1%
 30 2 0 2,2%
 36 3 1 4,4%
 39 2 0 2,2%
 40 29 (39%) 1 30 (33,3%)
 45 37 (49%) 11 (73%) 48 (53,3%)
 54 1 0 1,1%
 60 0 2 2,2%
Treatment duration, median (range) 8 days(3 – 22)